As of 2025-12-14, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -4.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 394.12 mil USD. ENTA's TTM EBITDA according to its financial statements is -80.76 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 15.0x | 14.6x |
| Forward P/E multiples | 14.2x - 22.3x | 18.3x |
| Fair Price | (38.55) - (40.85) | (45.03) |
| Upside | -361.7% - -377.3% | -405.7% |
| Date | EV/EBITDA |
| 2025-12-12 | -4.89 |
| 2025-12-11 | -4.67 |
| 2025-12-10 | -4.75 |
| 2025-12-09 | -4.85 |
| 2025-12-08 | -4.68 |
| 2025-12-05 | -4.83 |
| 2025-12-04 | -4.65 |
| 2025-12-03 | -4.70 |
| 2025-12-02 | -4.60 |
| 2025-12-01 | -4.67 |
| 2025-11-28 | -4.66 |
| 2025-11-26 | -4.60 |
| 2025-11-25 | -4.50 |
| 2025-11-24 | -4.49 |
| 2025-11-21 | -4.17 |
| 2025-11-20 | -3.95 |
| 2025-11-19 | -3.95 |
| 2025-11-18 | -4.03 |
| 2025-11-17 | -4.20 |
| 2025-11-14 | -3.93 |
| 2025-11-13 | -3.80 |
| 2025-11-12 | -3.88 |
| 2025-11-11 | -3.92 |
| 2025-11-10 | -3.73 |
| 2025-11-07 | -3.54 |
| 2025-11-06 | -3.48 |
| 2025-11-05 | -3.52 |
| 2025-11-04 | -3.48 |
| 2025-11-03 | -3.48 |
| 2025-10-31 | -3.53 |
| 2025-10-30 | -3.50 |
| 2025-10-29 | -3.41 |
| 2025-10-28 | -3.36 |
| 2025-10-27 | -3.37 |
| 2025-10-24 | -3.37 |
| 2025-10-23 | -3.43 |
| 2025-10-22 | -3.36 |
| 2025-10-21 | -3.55 |
| 2025-10-20 | -3.59 |
| 2025-10-17 | -3.55 |
| 2025-10-16 | -3.68 |
| 2025-10-15 | -3.79 |
| 2025-10-14 | -3.53 |
| 2025-10-13 | -3.72 |
| 2025-10-10 | -3.55 |
| 2025-10-09 | -3.71 |
| 2025-10-08 | -3.65 |
| 2025-10-07 | -3.58 |
| 2025-10-06 | -3.67 |
| 2025-10-03 | -3.31 |